Adagio Medical Holdings annual r&d spending
2021
2022
2023
2024
2025
Adagio Medical Holdings R&D Spending Growth & History (ADGM)
Adagio Medical Holdings's r&d spending was $10.6M for fiscal 2025.
View full Adagio Medical Holdings company overviewAdagio Medical Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.6M | $6.0M | +129.59% |
| 2024 | 2024-12-31 | $4.6M | −$10.8M | −69.91% |
| 2023 | 2023-12-31 | $15.4M | −$2.5M | −13.76% |
| 2022 | 2022-12-31 | $17.9M | $2.5M | +16.28% |
| 2021 | 2021-12-31 | $15.4M | — | — |
Adagio Medical Holdings quarterly r&d spending
Q3.23
Q1.24
Q2.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.5M | $479,000 | +24.30% |
| Q1 2026 | 2026-03-31 | $2.7M | −$918,000 | −25.09% |
| Q4 2025 | 2025-12-31 | $2.2M | — | — |
| Q3 2025 | 2025-09-30 | $2.8M | $1.6M | +127.94% |
| Q2 2025 | 2025-06-30 | $2.0M | −$894,000 | −31.20% |
| Q1 2025 | 2025-03-31 | $3.7M | $190,000 | +5.48% |
| Q3 2024 | 2024-09-30 | $1.2M | −$3.2M | −72.45% |
| Q2 2024 · Jul 30 | 2024-07-30 | $1.3M | — | — |
| Q2 2024 · Jun 30 | 2024-06-30 | $2.9M | — | — |
| Q1 2024 | 2024-03-31 | $3.5M | — | — |
| Q3 2023 | 2023-09-30 | $4.4M | — | — |
Adagio Medical Holdings r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Adagio Medical Holdings's r&d spending decreased from $15.4M to $10.6M, a change of −$4.7M. The latest reported quarter, Q2 2026, shows $2.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adagio Medical Holdings source filings ↗